ALLO Quote, Financials, Valuation and Earnings

Cardiff Oncology has a net margin of -295454.55% compared to Allogene Therapeutics's net margin of -12324.77%. Allogene Therapeutics's return on equity of -52.73% beat Cardiff Oncology's return on equity of -77.18%.

Allogene Therapeutics has a consensus price target of $8.15, signalling upside risk potential of 562.6%. On the other hand Cardiff Oncology has an analysts' consensus of $12.07 which suggests that it could grow by 173.11%. Given that Allogene Therapeutics has higher upside potential than Cardiff Oncology, analysts believe Allogene Therapeutics is more attractive than Cardiff Oncology.

Allogene Therapeutics has a beta of 0.308, which suggesting that the stock is 69.171% less volatile than S&P 500. In comparison Cardiff Oncology has a beta of 1.516, suggesting its more volatile than the S&P 500 by 51.624%.

Allogene Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cardiff Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics pays -- of its earnings as a dividend. Cardiff Oncology pays out -- of its earnings as a dividend.

Allogene Therapeutics quarterly revenues are $22K, which are smaller than Cardiff Oncology quarterly revenues of $109K. Allogene Therapeutics's net income of -$59.7M is lower than Cardiff Oncology's net income of -$13.4M. Notably, Allogene Therapeutics's price-to-earnings ratio is -- while Cardiff Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics is 2,916.87x versus 399.21x for Cardiff Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics has a net margin of -295454.55% compared to Allogene Therapeutics's net margin of 44.59%. Allogene Therapeutics's return on equity of -52.73% beat Halozyme Therapeutics's return on equity of 137.42%.

Allogene Therapeutics has a consensus price target of $8.15, signalling upside risk potential of 562.6%. On the other hand Halozyme Therapeutics has an analysts' consensus of $65.89 which suggests that it could grow by 13.58%. Given that Allogene Therapeutics has higher upside potential than Halozyme Therapeutics, analysts believe Allogene Therapeutics is more attractive than Halozyme Therapeutics.

Allogene Therapeutics has a beta of 0.308, which suggesting that the stock is 69.171% less volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.146, suggesting its more volatile than the S&P 500 by 14.574%.

Allogene Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Allogene Therapeutics quarterly revenues are $22K, which are smaller than Halozyme Therapeutics quarterly revenues of $264.9M. Allogene Therapeutics's net income of -$59.7M is lower than Halozyme Therapeutics's net income of $118.1M. Notably, Allogene Therapeutics's price-to-earnings ratio is -- while Halozyme Therapeutics's PE ratio is 15.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics is 2,916.87x versus 6.89x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -295454.55% compared to Allogene Therapeutics's net margin of -30140.49%. Allogene Therapeutics's return on equity of -52.73% beat Inovio Pharmaceuticals's return on equity of -125.47%.

Allogene Therapeutics has a consensus price target of $8.15, signalling upside risk potential of 562.6%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 459.7%. Given that Allogene Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Allogene Therapeutics is more attractive than Inovio Pharmaceuticals.

Allogene Therapeutics has a beta of 0.308, which suggesting that the stock is 69.171% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.734%.

Allogene Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Allogene Therapeutics quarterly revenues are $22K, which are smaller than Inovio Pharmaceuticals quarterly revenues of $65.3K. Allogene Therapeutics's net income of -$59.7M is lower than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Allogene Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics is 2,916.87x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals has a net margin of -295454.55% compared to Allogene Therapeutics's net margin of -2004.36%. Allogene Therapeutics's return on equity of -52.73% beat Lexicon Pharmaceuticals's return on equity of -90.8%.

Allogene Therapeutics has a consensus price target of $8.15, signalling upside risk potential of 562.6%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $2.58 which suggests that it could grow by 100%. Given that Allogene Therapeutics has higher upside potential than Lexicon Pharmaceuticals, analysts believe Allogene Therapeutics is more attractive than Lexicon Pharmaceuticals.

Allogene Therapeutics has a beta of 0.308, which suggesting that the stock is 69.171% less volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.928%.

Allogene Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Allogene Therapeutics quarterly revenues are $22K, which are smaller than Lexicon Pharmaceuticals quarterly revenues of $1.3M. Allogene Therapeutics's net income of -$59.7M is lower than Lexicon Pharmaceuticals's net income of -$25.3M. Notably, Allogene Therapeutics's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics is 2,916.87x versus 14.43x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.